It also means that combining medication with behavioral strategies, rather than relying on medication alone, produces the most resilient results

Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions

It gives us a lot more tools, she adds
Unfortunately, surgery is not always possible due to the size and location of the tumor, thus, a better understanding of MPNST initiation and development is required to design novel therapeutics
These improvements can help lower the long-term risk of heart disease, an important goal for many of our patients at Centra Internal Medicine
Contact your GP for reassessment if symptoms persist after starting treatment